U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Formulife, Inc. - 508605 - 03/02/2018
  1. Warning Letters

CLOSEOUT LETTER

Formulife, Inc. MARCS-CMS 508605 —

Recipient:
Formulife, Inc.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

Office of Human &Animal Food Operations, West Division 3
4040 North Central Expressway, Suite 300
Dallas, Texas 75204 
 
 

March 2, 2018

UPS Overnight

Brandon M. Smith, Owner and President
Formulife, Inc.
Purus Labs, Inc.
1253 Andrews Parkway
Allen, Texas 75002-2692

Dear Mr. Smith:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letters (2012-DAL-WL-12, January 18, 2012; 2013-DAL-WL-38, June 17, 2013; and 2017-DAL-WL-21, May 12, 2017). Based on our evaluation, it appears that you have addressed the violations contained in these Warning Letters. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Chad J. Whitwell
Acting Director, Compliance Branch
Human & Animal Food Operations, WD3 

Back to Top